Drugs / WRSs3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01336699 | Jan 2013 → May 2015 | shigellosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WRSs3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01336699 ↗ |
| Modality | Vaccine | “WRSs3 is a live, attenuated Shigella sonnei vaccine product” NCT01336699 ↗ |
| Route | Oral | “given orally” NCT01336699 ↗ |